Are tolerability concerns a class effect of beta-blockers in treating patients with hypertension?

Postgraduate Medicine

Volumn 121, Issue 1, 2009, Pages 14-24

  Kountz, David S ^a,b  

^a JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Beta blockers; Cardiovascular disease; Carvedilol; Hypertension; Labetalol; Nebivolol; Tolerability

Indexed keywords

ACEBUTOLOL; ADRENERGIC RECEPTOR; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; BUCINDOLOL; CARTEOLOL; CARVEDILOL; CELIPROLOL; CHLORTALIDONE; CIMETIDINE; ESMOLOL; HYDROCHLOROTHIAZIDE; LABETALOL; LIDOCAINE; LOSARTAN; METOPROLOL; NADOLOL; NEBIVOLOL; PINDOLOL; PLACEBO; PROPRANOLOL; SOTALOL; TIMOLOL;

ARTICLE; ASTHENIA; BLOOD PRESSURE REGULATION; BLURRED VISION; BRADYCARDIA; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; INTRINSIC SYMPATHOMIMETIC ACTIVITY; ISCHEMIC HEART DISEASE; MORTALITY; PARESTHESIA; RAYNAUD PHENOMENON; SEXUAL DYSFUNCTION; STROKE; SYNCOPE; VASODILATATION; XEROSTOMIA; CARDIOVASCULAR DISEASE; CLASSIFICATION; DRUG INTERACTION; DRUG TOLERANCE; META ANALYSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; DRUG TOLERANCE; HUMANS; HYPERTENSION; META-ANALYSIS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 60549100536     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.01.1951     Document Type: Article

References (70)

1. Rosamond W, Flegal K, Furie K, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-e146.
2. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007(1):CD002003.
3. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288(3):351-357. (Pubitemid 34761614)
4. Ubel PA, Jepson C, Asch DA. Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians. J Gen Intern Med. 2003;18(12):977-983. (Pubitemid 38091391)
5. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM. 2007;100(7):395-404. (Pubitemid 47062891)
6. Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens. 2006;24(11):2131-2141. (Pubitemid 44611017)
7. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177-186. (Pubitemid 46089734)
8. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34(4 pt 2):724-728. (Pubitemid 29501288)
9. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis. 1998;41(1 suppl 1):39-52. (Pubitemid 28381714)
10. Lopez-Sendon J, Swedberg K, McMurray J, et al; Task Force on Bela-Blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25(15):1341-1362. (Pubitemid 39004105)
11. Egan BM, Basile J, Chilton RJ, Cohen JD. Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich). 2005;7(7):409-416.
12. Frishman WH. A historical perspective on the development of beta-adrenergic blockers. J Clin Hypertens (Greenwich). 2007;9(4 suppl 3):19-27.
13. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9(4):269-277. (Pubitemid 47377026)
14. Ko DT, Hebert PR, Coffey CS, et al. Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med. 2004;164(13):1389-1394. (Pubitemid 38937849)
15. Hunt SA, Abraham WT, Chin MH, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154-e235.
16. Fogari R, Zoppi A, Tettamanti F, Poletti L, Rizzardi G, Fiocchi G. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther. 1990;4(4):1145-1149. (Pubitemid 20330480)
17. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006;99(7):431-436. (Pubitemid 44304843)
18. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of hypertension. Endocr Pract. 2006;12(2):193-222.
19. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100(8):1254-1262. (Pubitemid 47498283)
20. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201-207. (Pubitemid 46111014)
21. Beeley L. Drug interactions and beta-blockers. Br Med J (Clin Res Ed). 1984;289(6455):1330-1331.
22. Frishman WH. Beta-adrenergic receptor blockers. Adverse effects and drug interactions. Hypertension. 1988;11(3 pt 2):II21-II29.
23. Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet. 1996;30(6):416-444. (Pubitemid 26175753)
24. Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B. The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients. Br J Clin Pharmacol. 1984;17(suppl 1):108S-111S. (Pubitemid 14052253)
25. Watkins J, Abbott EC, Hensby CN, Webster J, Dollery CT. Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin. Br Med J. 1980;281(6242):702-705. (Pubitemid 10049416)
26. Douglas JG, Bakris GL, Epstein M, et al; Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163(5):525-541.
27. Ferdinand KC, Armani AM. The management of hypertension in African Americans. Crit Pathw Cardiol. 2007;6(2):67-71. (Pubitemid 46878235)
28. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care. 2006;29(6):1263-1268.
29. Messerli FH, Grossman E. Beta-blockers in hypertension: is carvedilol different? Am J Cardiol. 2004;93(9A):7B-12B.
30. George RB, Light RW, Hudson LD, et al. Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with asthma and propranolol sensitivity. Chest. 1985;88(6):815-818. (Pubitemid 16207496)
31. George RB, Manocha K, Burford JG, Conrad SA, Kinasewitz GT. Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. Chest. 1983;83(3):457-460. (Pubitemid 13156487)
32. Carter BL. Labetalol. Drug Intell Clin Pharm. 1983;17(10):704-712.
33. Giles TD, Weber M, Bartels DW, et al. Evaluation of labetalol in elderly patients with essential hypertension. J Clin Pharmacol. 1991;31(6):556-560.
34. Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther. 2003;100(3):215-234. (Pubitemid 37494907)
35. Afonso RA, Patarrao RS, Macedo MP, Carmo MM. Carvedilol action is dependent on endogenous production of nitric oxide. Am J Hypertens. 2006;19(4):419-425.
36. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349-1355.
37. Weber MA, Bakris GL, Tarka EA, Iyengar M, Fleck R, Sica DA. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006;8(12):840-849.
38. Packer M, Fowler MB, Roecker EB, et al; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194-2199.
39. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13. (Pubitemid 36835815)
40. Henderson LS, Tenero DM, Baidoo CA, et al. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am J Cardiol. 2006;98(7A):17L-26L. (Pubitemid 44470745)
41. Veverka A, Nuzum DS, Jolly JL. Nebivolol: a third-generation beta-adrenergic blocker. Ann Pharmacother. 2006;40(7-8):1353-1360.
42. Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs. 2008;8(1):35-44.
43. Czuriga I, Riecansky I, Bodnar J, et al; NEBIS Investigators Group. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther. 2003;17(3):257-263. (Pubitemid 37421743)
44. Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl. 2003;2:35-40. (Pubitemid 38112143)
45. Rosei EA, Rizzoui D, Comini S, Boari G; Nebivolol-Lisinopril Study Group. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press Suppl. 2003;1:30-35. (Pubitemid 36681970)
46. Uhlir O, Fejfusa M, Havranek K, et al. Nebivolol versus metoprolol in the treatment of hypertension. Drug Invest. 1991;3(suppl 1):107-110.
47. Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens. 2005;18(8):1060-1066. (Pubitemid 41139904)
48. Van Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JI, A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens. 1997;11(2):139-144. (Pubitemid 27202257)
49. Van Nueten L, Lacourciere Y, Vyssoulis G, et al. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther. 1998;5(4):237-243. (Pubitemid 28373710)
50. Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1997;11(12):813-819. (Pubitemid 28043340)
51. Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1998;12(2):135-140. (Pubitemid 28062129)
52. Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich). 2007;9(9):667-676.
53. Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol. 2007;34(4):327-331. (Pubitemid 46257045)
54. Boydak B, Nalbantgil S, Fici F, et al. A randomised comparison of the effects of nebivolol and atenolol with and without chlorthalidone on the sexual function of hypertensive men. Clin Drug Investig. 2005;25(6):409-416. (Pubitemid 41019988)
55. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227-2237. (Pubitemid 39473160)
56. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70(11):1905-1913. (Pubitemid 44863377)
57. Torp-Pedersen C, Metra M, Charlesworth A, et al; COMET Investigators. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007;93(8):968-973. (Pubitemid 47122050)
58. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24(3):591-596. (Pubitemid 43261924)
59. Poirier L, Cléroux J, Nadeau A, Lacourcière Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens. 2001;19(8):1429-1435. (Pubitemid 32730460)
60. Flamenbaum W, Weber MA, McMahon FG, Materson BJ, Carr AA, Poland M. Monotherapy with labetalol compared with propranolol. Differential effects by race. J Clin Hypertens. 1985;1(1):56-69.
61. Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007;9(11):866-875.
62. Wright JT Jr, Bakris GL, Bell DS, et al. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI trial. J Clin Hypertens (Greenwich). 2007;9(11):842-849.
63. Phillips RA, Fonseca V, Katholi RE, et al. Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in subjects with type 2 diabetes and hypertension in the GEMINI study. J Cardiometab Syndr. In press.
64. Abraham WT, Massie BM, Lukas MA, et al; COHERE Participant Physicians. Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry. Congest Heart Fail. 2007;13(1):16-21.
65. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA. 1977;237(3):255-261. (Pubitemid 8031248)
66. Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
67. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society: endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117(2):296-329.
68. Fraker TD Jr, Fihn SD, Gibbons RJ, et al; American College of Cardiology; American Heart Association; American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation. 2007;116(23):2762-2772.
69. National Collaborating Centre for Chronic Conditions, Hypertension: Management of Adults in Primary Care: Pharmacological Update. London, England: Royal College of Physicians; 2006.
70. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462-1536.